$1.80
-0.07 (-3.74%)
Open$1.83
Previous Close$1.87
Day High$2.08
Day Low$1.74
52W High$39.00
52W Low$3.61
Volume—
Avg Volume72.1K
Market Cap8.11M
P/E Ratio—
EPS$-10.99
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+160.0% upside
Current
$1.80
$1.80
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.68M | 26.31M | 3.13M |
| Net Income | -20,616,673 | -19,013,224 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -15,075,068 | -14,674,981 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |